Right now, the swarm's clearest reading is a wall that isn't moving. Both psilocybin and ibogaine stay in Schedule I — the government's most restricted drug category, meaning no legal medical use — for the next twelve months. Multiple simulated experts, including one playing a drug-enforcement officer and one playing a lawmaker, agree: there's no bill moving through Congress, no formal request to change the rules that's close to a decision, and no finished proof strong enough to force the government's hand. On the money side, the companies chasing these medicines — like Compass Pathways and Atai — dropped again today (Compass down about 4%, Atai down about 6%). Their stocks are expected to stay flat or drift lower until one of them delivers results from a large, final-stage human study, and none is on the calendar. No new psychedelic will win federal approval this year beyond ketamine's cousin, esketamine, which is already cleared.
Beneath the news is a quieter, more hopeful story. The real action isn't in the courtroom or the stock ticker — it's in the lab. Scientists are working to build versions of ibogaine that keep the healing power but strip out the danger. Raw ibogaine can strain the heart, which is exactly why regulators move slowly with it. So researchers are designing safer cousins of the molecule. The swarm gives this real odds of moving forward this year. This is the honest, sturdy path: not rushing a risky plant onto the market, but doing the patient work to make it safe first. Meanwhile, the media is starting to grow up too — trading the "miracle cure" headlines for a more careful, truthful picture. That maturing is a good sign, not a bad one.
For the people inside this story, the wait is not abstract. Veterans carrying deep wounds from war, families watching someone they love disappear into addiction or depression — they don't have twelve months to spare, and they know it. That ache is real, and it's why the most important line in today's reading is this: a state or veterans' program is likely to open access before Washington ever acts. Texas and Arizona are already paying for ibogaine research. The help may come first from a neighbor, a state, a small program run by people who simply refused to keep waiting. For someone who has run out of options, that local door opening is everything. The highest path here is not a distant federal blessing — it's the safer medicine being built now, and the local courage bringing it to the people who need it most, sooner.
The science is catching up to what the plants have always known. OOTW exists at that exact moment of convergence — the data and the mystery meeting each other.
This is not prediction. This is recognition.
85%
Psilocybin and ibogaine stay in the most restricted drug category
The US federal government keeps psilocybin (magic mushrooms) and ibogaine (a plant-based psychedelic) in Schedule I — the same legal bucket as heroin — for at least another year. This means no doctor can prescribe them, and researchers need special government permission just to study them. Nothing on the horizon is likely to change that.
→ Psilocybin and ibogaine remain federally illegal for at least another year, and no serious effort to change that is close to succeeding. Confidence: 85%
Resolves: 2027-07-06 · USA
REGULATORY
the precise call ▾
Psilocybin and ibogaine remain Schedule I federally throughout the next 12 months.. No legislative vehicle, no DEA petition near resolution. Scheduling changes require completed medical evidence we don't have. Status quo holds.
82%
Federal government won't reclassify psychedelics anytime soon
Experts across law enforcement, lawmaking, and drug regulation all agree: the federal government won't move psychedelics out of their current most-restricted category within the next year. One expert disagreed, but the strong consensus says the legal status stays frozen. This matters because reclassification would unlock research, insurance coverage, and potentially legal medical use.
→ A strong expert consensus says no federal reclassification is coming in the next 12 months. Confidence: 82%
Resolves: 2026-10-04 · USA
REGULATORY
the precise call ▾
No federal rescheduling of psilocybin or ibogaine within 12 months.. Consensus of 3 agents: dea_officer, legislator, fda_reviewer. 1 dissenting.
78%
No new psychedelic drug gets full federal approval in the next year
Right now, the only psychedelic-like drug the FDA (the US drug regulator) has fully approved is esketamine, a nasal spray for depression. No other psychedelic will join it in the next 12 months. The company behind MDMA-assisted therapy has to do more research before regulators will consider approving it. This matters because FDA approval is what lets doctors prescribe a drug and insurance companies pay for it.
→ No psychedelic drug beyond the already-approved esketamine nasal spray will get full FDA approval in the next 12 months. Confidence: 78%
Resolves: 2027-07-06 · USA
REGULATORY
the precise call ▾
No FDA approval of any psychedelic beyond esketamine within 12 months; MDMA NDA path requires additional data.. The agency won't move on hype. Ibogaine framing is preclinical/analogue-focused. Esketamine remains the only cleared novel agent; real approvals need clean Phase 3 packages.
80%
Psychedelic company stock prices stay flat or keep falling through early 2027
Publicly traded psychedelic companies like Compass Pathways and ATAI Life Sciences are expected to stay stuck in a rut or lose more value until they publish major drug trial results. Big professional investors are sitting out, the excitement that drove prices up earlier has faded, and there's no obvious near-term event to spark a recovery. Real people who own shares in these companies could keep losing money.
→ Psychedelic biotech stocks are expected to stay depressed until a major trial result or buyout shakes things up. Confidence: 80%
Resolves: 2027-01-06 · Global
MARKET
the precise call ▾
Psychedelic biotech names (CMPS, ATAI) remain range-bound to lower through Q1 2027 absent a Phase 3 readout.. No de-risking catalyst on the calendar. Institutional capital sits out. Retail hype exhausted. Multiples compress until data or M&A.
78%
Congress won't pass any law expanding psychedelic access this year
No federal law making psychedelics easier to access or research will pass in the next 12 months. Politicians in Washington are too focused on taxes and other priorities, and psychedelic reform doesn't have enough political cover to get a vote. This means the patchwork of state laws — some states allow certain uses, others don't — stays the only real avenue for change.
→ Congress will not pass any law expanding psychedelic access in the next year — state programs are the only game in town. Confidence: 78%
Resolves: 2027-07-06 · USA
LEGISLATION
the precise call ▾
No federal psychedelic rescheduling or access statute enacted within 12 months.. Congress is consumed by tax and surveillance priorities. Psychedelic reform lacks a must-pass vehicle. I can't get ahead of my district without cover.